Measure ID
NMB-01
Domain
Description

Percentage of patients with a documented Train of Four (TOF) after last dose of non-depolarizing neuromuscular blocker.

Measure Type
Process
Available for Provider Feedback
Yes
Threshold
90%
Rationale

Postoperative residual neuromuscular blockade can lead to significant complications such as hypoxemia, impaired pulmonary function, upper airway obstruction, postoperative pneumonia, and respiratory failure.1,2 Several studies have found associations between the use of neuromuscular blockade agents (NMBA) and residual neuromuscular blockade in the recovery room. 1, 5-6  Adverse postoperative respiratory outcomes are even more frequent when patients receive NMBA and reversal agents are not used. 1-4 A mainstay of residual blockade prevention continues to be monitoring to allow for detection, and use of reversal agents like neostigmine and Sugammadex. Due to variability in duration of muscle relaxants, even in defasciculating doses, we recommend that TOF is monitored when any non-depolarizing neuromuscular blockers are administered.

Measure Time Period
Inclusions

All patients that have received either by bolus or infusion a non-depolarizing neuromuscular blocker (NMB) AND were extubated post-operatively or in the PACU.  The following NMBs are included:

  • Atracurium
  • Cisatracurium
  • Pancuronium
  • Rocuronium
  • Vecuronium
Exclusions
  • ASA 5 and 6 including Organ Procurement (CPT: 01990)
  • Patients not receiving neuromuscular blockade
  • Patients that were not extubated in the immediate postoperative period (as defined by the earliest time resulted from LMA Removal Times or Extubation Times).
  • Procedure Type: Lung Transplant
Success Criteria

Documentation of a Train of Four count (1, 2, 3, or 4), sustained tetany, or TOF ratio provided by acceleromyography AFTER last dose or stopping of infusion of neuromuscular blocker and before earliest extubation.  Note: A Train of Four value of ‘0’ is accepted for cases in which sugammadex is administered for reversal.

Other Measure Details

*This measure will include valid MPOG cases defined by the Is Valid Case MPOG phenotype.

Risk Adjustment

Not Applicable

Provider Attribution

The provider(s) signed in at time of earliest extubation.

MPOG Concept Used

Neuromuscular Blocker Medications

  • 10043 Atracurium
  • 10129 Cisatracurium
  • 10344 Pancuronium
  • 10393 Rocuronium
  • 10446 Vecuronium

Extubation

  • 50127 Intubation Extubated Awake or Deep
  • 50202 Emergence- Patient Extubated
  • 50145 Airway – Laryngeal mask airway removed (deep or awake)

Train of Four

  • 3033  Train-of-four objective count (acceleromyography, electromyography, other)
  • 3330  Train-of-four (Subjective assessment)
  • 3485  Train-of-four Quantitative (Objective) Ratio
MPOG Phenotypes Used
Case Report Return Columns
References
  1. Thilen SR, Weigel WA, Todd MM, Dutton RP, Lien CA, Grant SA, Szokol JW, Eriksson LI, Yaster M, Grant MD, Agarkar M, Marbella AM, Blanck JF, Domino KB: 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade. Anesthesiology 2023; 138:13–41
  2. Harrison GG. Death attributable to anaesthesia. A 10-year survey (1967-1976). Br J Anaesth 1978; 50:1041-6.
  3. Beecher HK, Todd DP. A study of the deaths associated with anesthesia and surgery: based on a study of 599, 548 anesthesias in ten institutions 1948-1952, inclusive. Ann Surg 1954; 140:2-35.
  4. Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesth Analg. 2010. 111(1): 129-40.
  5. Grosse-Sundrup M, Henneman JP, Sandberg WS, Bateman BT, Uribe JV, Nguyen NT, Ehrenfeld JM, Martinez EA, Kurth T, Eikermann M. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ 2012; 345:e6329
  6. Lien CA, Kopman AF. Current recommendations for monitoring depth of neuromuscular blockade. Curr Opin Anesthesiol. 2014; 27(6): 616-622.
Measure Authors

 Measure Author

 Institution

 Nirav Shah, MD

 University of Michigan

 Sachin Kheterpal, MD

 University of Michgan

 Jaime Osborne, RN

 University of Michigan

 Genevieve Bell

 University of Michigan

 MPOG Quality Commiittee

 

 

Measure Reviewer(s)
Next Review: 2024
 Date Reviewed  Reviewer  Institution  Summary  QC Vote

 09/2021

 Alvin Stewart

 Peter Panagopolous

 UAMS

 Corewell East - Dearborn

 Review

  No change

Version

Published Date: 02/2015

 Date

 Criteria

 Revision

 03/06/2024  Exclusion

 Added Lung Transplants as exclusion

 12/04/2023

 Measure Time Period

 Added time check for LMA removal

 02/28/2022

 Exclusion

 Removed cardiac procedure exclusion

 11/09/2021

 Exclusion

 Modified cardiac case exclusion to use new Cardiac Phenotype